12:21 PM EDT, 10/22/2025 (MT Newswires) -- Armata Pharmaceuticals ( ARMP ) said its investigational bacteriophage therapy AP-SA02 achieved higher clinical response rates than placebo in a phase 2a study in patients with complicated Staphylococcus aureus bacteremia.

Data showed day 12 clinical response rates for AP-SA02 combined with best available therapy at 88% as assessed by blinded site investigators and 83% as evaluated by the blinded adjudication committee, compared with 58% for placebo, the company said.

No patients treated with AP-SA02 experienced relapse or non-response during follow-up, compared with about 25% in the placebo group, Armata said.

The therapy was well tolerated with no serious adverse events related to treatment, the company added.

Armata said the findings support advancing AP-SA02 into a phase 3 trial in 2026, subject to review and feedback from the US Food and Drug Administration.

Shares of Armata rose more than 58% in recent trading Wednesday.

Price: 5.50, Change: +2.03, Percent Change: +58.50